ACC: AstraZeneca’s clot-busting Brilinta matches Plavix safety in high-risk heart attack patients

AstraZeneca just may have found a new niche for blood thinner Brilinta. Sunday, the British pharma giant presented data showing the med was as safe as the standard therapy clopidogrel—known in the branded world as Sanofi’s Plavix—when used to treat some high-risk heart attack patients.Original Article